| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| MediChem Life Sciences, Inc. |
| 12305 South New Avenue, Lemont, IL 60439 * (630) 257-1500 |
| Business Description | The company is a drug discovery technology and services company that offers a broad range of integrated chemistry R&D; capabilities to pharmaceutical and biotechnology companies. |
| Offering Information Company has | |||
| Trading As | MCLS (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Class A Common Shares | Filing Date | 6/16/00 |
| Domestic Shares Offered | 6,400,000 | Offer Date | 10/25/00 |
| Foreign Shares Offered | 0 | Filing Range | $7.00 - $9.00 |
| Company Shares | 6,400,000 | Offer Price | $7.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.490 |
| Gross Proceeds | $44,800,000 | Selling | $0.280 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 25,379,223 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| UBS Warburg LLC | Co-manager | |
| William Blair & Company | Co-manager | (312) 364-8990 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 5.546 | 8.620 | 13.558 | 2.568 | 4.142 |
| Income from Oper. | - | - | 0.491 | 0.878 | 2.510 | -0.096 | 0.238 |
| Net Income | - | - | 0.267 | 0.320 | 1.070 | -0.072 | -1.847 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | - | - | 55.42 | 57.298 | 61.29 | ||
| Net Income Growth (%) | - | - | 19.73 | 234.85 | - | ||
| Oper. Profit Margin (%) | - | - | 8.85 | 10.19 | 18.51 | 5.74 | - |
| Net Profit Margin (%) | - | - | 4.81 | 3.71 | 7.89 | - | - |
| Cash Flow - Oper. | 1.71 | 0.25 | -1.14 | ||||
| Cash Flow - Inv. | -4.22 | -0.26 | -2.30 | ||||
| Cash Flow - Fin. | 10.65 | 0.28 | -2.06 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 14.78 | Current Assets | 6.21 | Current Ratio | 1.72 |
| Total Liab. | 25.51 | Current Liab. | 3.61 | Debt Ratio | 172.60% |
| Total Equity | -10.73 | Working Cap. | 2.60 | Debt to Equity Ratio | - |
| Cash | 2.66 | Return on Assets | 7.24% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes including funding expansion of operations, hiring additional personnel, platform technologies R&D;, and potential acquisitions as well as repayment of indebtedness, redemption of existing capital stock and warrants, and investment in ALS. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Winston & Strawn |
| Bank's Law Firm | Dewey Ballantine |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| ChaseMedichem Partners, LLC | 18.85 | |
| Peachtree Medichem Partners LLC | 10.95 | |
| MedEquity Investors Partners LLC | 1.98 | |
| Note: represents ownership of 5% or more prior to the offering. | ||